91 studies found for:    coronado
Show Display Options
Rank Status Study
1 Not yet recruiting TSO for Plaque Psoriasis
Condition: Plaque Psoriasis
Intervention: Biological: Trichuris Suis Ova
2 Active, not recruiting Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure
Condition: Acute Alcoholic Hepatitis
Interventions: Biological: ELAD  treatment;   Other: Standard of care (Control)
3 Unknown  Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Condition: Crohn's Disease
Interventions: Biological: Trichuris suis ova (TSO);   Biological: Placebo
4 Active, not recruiting Trichuris Suis Ova in Autism Spectrum Disorders
Condition: Autism
Intervention: Drug: Trichuris Suis Ova
5 Terminated Safety and Efficacy of Roflumilast and Pioglitazone in Treating Adults With Nonalcoholic SteatoHepatitis
Condition: Nonalcoholic Steatohapatitis
Interventions: Drug: Roflumilast;   Drug: Pioglitazone;   Drug: Placebo
6 Recruiting Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo in Autism Spectrum Disorder
Condition: Autism
Interventions: Biological: Trichuris suis ova;   Other: Placebo
7 Recruiting CNDO-109-AANK for AML in First Complete Remission (CR1)
Condition: Acute Myeloid Leukemia
Intervention: Biological: CNDO-109-AANK Cells
8 Completed
Has Results
Safety and Tolerability of Single Doses Oral CNDO 201 Trichuris Suis Ova in Patients With Crohn's Disease
Condition: Crohn's Disease
Interventions: Biological: Trichuris suis ova;   Other: Placebo
9 Completed
Has Results
A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment
Condition: Hepatitis C, Chronic
Interventions: Drug: Telaprevir;   Drug: Peg-IFN-alfa-2a;   Drug: Ribavirin;   Drug: Placebo
10 Completed
Has Results
Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis
Condition: Chronic Hepatitis C Infection
Interventions: Drug: Fuzheng Huayu;   Drug: Placebo
11 Unknown  Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection
Condition: Hepatitis C, Chronic
Interventions: Drug: PEG-rIL-29;   Drug: Peginterferon alfa-2a;   Drug: Ribavirin
12 Completed GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus
Condition: Hepatitis C, Chronic
Interventions: Drug: GS-5885;   Drug: GS-9451;   Biological: peginterferon alfa-2a;   Drug: ribavirin tablet;   Drug: GS-9451 Placebo
13 Recruiting The Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy
Condition: Hepatic Encephalopathy
Interventions: Drug: Placebo;   Drug: Rifaximin
14 Completed
Has Results
VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo
Condition: Hepatitis C, Chronic
Interventions: Drug: Telaprevir;   Drug: pegylated interferon (Peg-IFN) alfa-2a;   Drug: ribavirin (RBV)
15 Completed Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects
Condition: Hepatitis C, Chronic
Interventions: Drug: GSK2336805;   Drug: Pegylated interferon alfa-2a;   Drug: Ribavirin;   Drug: GSK2336805 Matching Placebo
16 Recruiting A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 Infection
Conditions: Chronic Hepatitis C;   Hepatitis C Virus;   HCV
Interventions: Drug: ABT-493;   Drug: ABT-530
17 Active, not recruiting Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis
Condition: Liver Cirrhosis
Interventions: Drug: Placebo;   Drug: Rifaximin SSD 40 mg IR tablet;   Drug: Rifaximin SSD 80 mg IR tablet;   Drug: Rifaximin SSD 40 mg SER tablet;   Drug: Rifaximin SSD 80 mg SER tablet;   Drug: Rifaximin SSD 80 mg IR tablet + rifaximin SSD 80 mg SER tablet
18 Completed Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care
Condition: Chronic Hepatitis C
Interventions: Drug: BMS-790052;   Drug: BMS-650032;   Drug: Pegylated-interferon alfa-2a;   Drug: Ribavirin
19 Completed
Has Results
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
Condition: Chronic Hepatitis C Infection
Interventions: Drug: ABT-450/r/ABT-267;   Drug: ABT-333;   Drug: Ribavirin;   Drug: Placebo for ribavirin
20 Active, not recruiting Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications
Condition: Chronic Hepatitis C
Interventions: Drug: BMS-650032;   Drug: BMS-790052;   Drug: BMS-791325;   Drug: Ribavirin

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years